3D BioFibR
Manufactures high-quality collagen fibers at commercial scale using a patented dry-spinning process for tissue engineering, 3D cell culture, and bioprinting applications.
- CEO / Founder
- Kevin Sullivan
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $4.77M
- Latest Round
- Seed
- Key Investors
- Concrete Ventures, Innovacorp, NGen, Build Ventures
Technology & Products
Key Products
["CollaFibR™ scaffold","μCollaFibR™ (micro-CollaFibR) bioink additive","Custom Scaffolds"]
Technological Advantage
Scalable and cost-effective manufacturing of collagen fibers that mimic the natural extracellular matrix, providing a superior micro-environment for cell growth compared to hydrogels. This enables more accurate and predictive tissue models for research and drug development.
Differentiation
Value Proposition
Providing biocompatible, structurally sound collagen fibers at a commercial scale, enabling the creation of more physiologically relevant and complex tissue models that are not possible with traditional hydrogels.
How They Differentiate
Unlike competitors that primarily offer collagen as hydrogels or sponges, 3D BioFibR's dry-spinning technology produces individual, high-fidelity collagen fibers. This allows for the creation of scaffolds with controlled architecture that better mimic the structure of natural tissue, providing a more physiologically relevant environment for cells.
Market & Competition
Target Customers
Researchers and companies in tissue engineering, regenerative medicine, 3D cell culture, and bioprinting.
Industry Verticals
["Biotechnology","Pharmaceuticals","Medical Research","Regenerative Medicine"]
Competitors
Advanced BioMatrix; CollPlant; Humabiologics
Growth & Milestones
Major Milestones
["Secured $3.52M in an oversubscribed seed funding round (July 2023).","Launched first commercial products: CollaFibR scaffold and μCollaFibR bioink additive (June 2023).","Established collaboration with PlantForm Corp and received $1.3M from NGen to scale manufacturing (January 2024).","Signed development agreement with Australian medical device company ReNerve.","Signed partnership with OkaSciences to bundle bioprinting materials."]
Notable Customers
While specific customer names are not public, the company targets research institutions and pharmaceutical companies. Partnerships with ReNerve and OkaSciences indicate adoption by device and material companies.